Monte Rosa Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Financial statements are unaudited. Monte Rosa is a pre-commercial biotechnology company developing molecular glue degraders (MGDs) using its QuEEN platform; it reported no product revenue.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Research and development expense | $28.3 million | $21.3 million | $84.1 million | $60.2 million |
| General and administrative expense | $8.7 million | $7.0 million | $24.3 million | $19.7 million |
| Total operating expenses | $37.0 million | $28.4 million | $108.4 million | $79.9 million |
| Net loss | $34.9 million | $27.3 million | $102.1 million | $77.7 million |
| Basic and diluted loss per share | $0.70 | $0.58 | $2.06 | $1.67 |
| Net cash used in operating activities | Not separately stated | Not separately stated | $73.4 million | $68.5 million |
Interest income was $2.2 million for Q3 and $7.0 million for the nine months, up from $1.0 million and $1.8 million, respectively, largely due to higher interest rates. Operating margins are not meaningful because the company had no revenue.
At September 30, cash and cash equivalents were $59.1 million and marketable securities were $119.4 million, totaling $178.5 million; restricted cash was a further $4.5 million. The company reported $183.0 million in cash, cash equivalents, restricted cash and marketable securities combined. It stated these resources were expected to fund operating expenses and capital requirements for at least 12 months from issuance of the interim financial statements. Accumulated deficit was $332.6 million.
Total liabilities were $67.6 million, including $46.4 million of operating lease liabilities. No credit facility or committed funding source was in place; the filing does not present a separate conventional debt balance. Current assets were $182.9 million and current liabilities $22.6 million. There were no dividends.
Changes versus the prior comparable period
- Nine-month net loss increased $24.4 million year over year, while operating cash use increased $4.9 million.
- Nine-month R&D expense rose $23.9 million, primarily from expanded research activity, increased headcount and facilities, and higher external research and development costs. G&A expense increased $4.6 million, principally reflecting personnel and public-company support costs.
- Cash and marketable securities excluding restricted cash declined from $262.8 million at December 31, 2022 to $178.5 million at September 30, 2023. Marketable securities declined as maturities and sales exceeded purchases, alongside operating spend and property and equipment purchases.
- Property and equipment, net, increased to $35.0 million from $27.1 million at year-end 2022. The company spent $17.4 million on property and equipment during the first nine months.
Outlook, developments and risks
- Management expects continuing operating losses and negative operating cash flows, with R&D, G&A and capital expenditures expected to increase. Further financing will be needed for future discovery, preclinical and clinical work; no assurance is given that funding or collaborations will be available on acceptable terms.
- R&D priorities included MRT-2359 clinical development, IND-enabling work for VAV1-directed MRT-6160, and programs involving CDK2, NEK7 and sickle cell disease targets. In October 2023, the company reported interim Phase 1 dose-escalation data for MRT-2359 indicating favorable tolerability, pharmacokinetic and pharmacodynamic profiles in heavily pretreated patients; results are preliminary and may change after review of final data.
- On October 16, 2023, Monte Rosa entered a Roche collaboration to discover and develop MGDs for cancer and neurological disease targets. The company is to receive a $50.0 million upfront payment, may receive contingent research, development, regulatory and sales payments exceeding $3 billion, and is entitled to tiered royalties. Roche may elect to continue development and commercialization at its own cost.
- On October 30, 2023, the company sold pre-funded warrants for 10,000,400 shares for gross proceeds of $25.0 million before offering expenses. The warrants are immediately exercisable at $0.0001 per share, creating potential dilution.
- Risks include uncertain clinical and regulatory outcomes, the possibility preliminary MRT-2359 data differ from final results, continued funding needs, and potential disruption from economic, geopolitical or public-health events. The company reported no material litigation and stated disclosure controls were effective as of September 30, 2023.
Key facts for investors to verify
- Whether the stated minimum 12-month runway assumptions remain valid after the October collaboration and warrant offering, and how the upfront payment and offering proceeds affect cash available.
- Final MRT-2359 clinical data, trial progress and timing, and development milestones for MRT-6160 and other pipeline programs.
- Roche agreement payment conditions, target scope, option terms, and the timing and contingencies for potential milestone and royalty revenue.
- Future operating cash burn, capital spending and financing needs, including the impact of potential warrant exercise and equity dilution.
- Lease obligations: reported operating lease liability of $46.4 million and undiscounted future minimum payments of $70.6 million.